Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention.
about
Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids.Glycosyl-Phosphatidyl-Inositol (GPI)-Anchors and Metalloproteases: Their Roles in the Regulation of Exosome Composition and NKG2D-Mediated Immune RecognitionNKG2D Ligands in Tumor Immunity: Two Sides of a CoinThe new deal: a potential role for secreted vesicles in innate immunity and tumor progressionIncreasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognitionNKG2D Receptor and Its Ligands in Host DefenseIncreased sMICA and TGFβ1 levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells.Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association studyFailure recovery of circulating NKG2D(+)CD56(dim)NK cells in HBV-associated hepatocellular carcinoma after hepatectomy predicts early recurrenceImmunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function declineAssociations of MICA Polymorphisms with Inflammatory Rheumatic Diseases.Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer.Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors.Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia.Role of Distinct Natural Killer Cell Subsets in Anticancer Response.Antibody targeting soluble NKG2D ligand sMIC refuels and invigorates the endogenous immune system to fight cancer.Anti-NKG2D mAb: A New Treatment for Crohn's Disease?Allele Specific Expression of MICA Variants in Human Fibroblasts Suggests a Pathogenic Mechanism.Extracellular vesicles as an efficient nanoplatform for the delivery of therapeutics.Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.ULBP1 is induced by hepatitis C virus infection and is the target of the NK cell-mediated innate immune response in human hepatocytes.Ultrasound-guided radiofrequency ablation enhances natural killer-mediated antitumor immunity against liver cancer.Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical OutcomePositive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression
P2860
Q27329648-9822F148-EB06-4FF1-9FB9-A3E7A44BF921Q28076151-8A849026-B789-40EB-AA4E-A3BCCFDC8E65Q28083832-4593F046-3416-4B8E-82DC-DB383B8442DFQ28084891-56701359-09DA-4A23-9BC9-377950452457Q33761979-F2BC96AB-614A-4FA2-8F5C-7B56533BB644Q35687826-7FF219F7-1132-41FE-8CDA-CC32A87B0F87Q36110266-52B96662-DC33-443F-95CF-AB66C17F5758Q36211604-F2585522-A7BE-4F75-ABCA-E5BAEF8A2E05Q36597366-10E062E6-8273-49C4-82A6-A472EFDD8A9CQ36711007-B2763DCE-F254-419A-BBF5-EF54B13E83CBQ37316220-E30D3414-8356-4F46-A3A3-0367075F4F7FQ38257969-9C15D8F7-59F7-4E15-84FD-FAA5C5717E26Q38829403-E45EFF0F-1CD3-4B77-B5EC-E9C4EF7E173FQ38860610-5E4D0989-D26A-4781-9EAC-4ACF2A87DAF6Q38940720-00301716-4711-4208-85CC-FF679F58B30EQ39210022-8D06556C-97E0-429F-8FA5-C7ACDCE9FC6AQ40436097-DE753025-B379-49FC-9501-9BA04BCF2E41Q41660377-8468A2AB-699B-4A9B-BB13-6774CF1C2D27Q42905223-93AA4355-385F-4BEB-91DF-AC37183C513BQ47741822-0370AC6B-A1F3-4BAA-8EB9-C7B0AECD88C1Q52758918-561976D9-EA1A-482A-8807-C5A693364760Q54261012-007B0537-3596-4827-91E9-33FFFAAAF4B1Q55083885-8D172E5A-9EE1-4A9E-8C6F-BAE013847D60Q56888827-510C595B-CA6C-4BED-89B8-9D69B3254807Q57300020-B7A00678-063D-488A-8D40-340CC0B06405
P2860
Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Secretory pathways generating ...... for therapeutic intervention.
@en
Secretory pathways generating ...... for therapeutic intervention.
@nl
type
label
Secretory pathways generating ...... for therapeutic intervention.
@en
Secretory pathways generating ...... for therapeutic intervention.
@nl
prefLabel
Secretory pathways generating ...... for therapeutic intervention.
@en
Secretory pathways generating ...... for therapeutic intervention.
@nl
P2860
P356
P1433
P1476
Secretory pathways generating ...... s for therapeutic intervention
@en
P2093
Beatriz Suarez-Álvarez
P2860
P304
P356
10.4161/ONCI.28497
P577
2014-04-25T00:00:00Z